Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Investigating the Effects of AGO1 Variants on iPSC-derived Neurons and Glial Cells

FY 2024-25

Summary
Small non-coding RNAs, namely microRNAs, are major contributors to the fine tuning of gene regulation in a wide array of organisms. microRNAs partner with effector proteins called Argonautes (AGOs), then guide the AGO to target mRNAs to silence gene expression. Recently, heterozygous de novo coding variants in human AGO1 and AGO2 have been shown to disrupt both neural and physical development, thereby directly implicating these variants in a rare neurodevelopmental disorder referred to as Argonaute syndrome. In this study, we are looking to examine the molecular and cellular effects of three specific AGO1 variants: p.(Phe180del), p.(Val254Ile) and p.(His751Leu) on iPSC-derived neurons and glial cells to gain a better understanding of the functions of AGO1, its effect on its small RNA pathways and its influence on cellular pathology in the context Argonaute syndrome. We will perform small RNA-seq, mRNA-seq and Ribo-seq in wild type vs. AGO1 variant cell lines to understand the effects of AGO1 variants on translation as well as the mRNA and sRNA transcriptome. This will broaden our understanding of which small RNAs and mRNA targets are mis-regulated upon AGO1 mutation, and how AGO1 regulates its targets in relevant cell lines. Additionally, we will examine the effects of the AGO1 variants on cellular morphology and neuronal activity using immunofluorescence microscopy and calcium imaging, respectively. This will allow us to gain a more comprehensive view of how these variants are influencing cellular physiology and pathology. The completion of this work will help to reveal critical fundamental information about the mechanisms of Argonaute syndrome, ultimately facilitating the development of novel therapeutic approaches for the treatment of this rare disease.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529972
Name
Rughani Ellanore
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Effects of AGO1 Variants on iPSC-derived Neurons and Glial Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Argonaute Syndrome; Cellular Pathology; Glia; Intellectual Disability; Ipsc; Neurodevelopmental Disorder; Neurons; Rare Disease; Rna Transcriptome; Translation
Abstract
Small non-coding RNAs, namely microRNAs, are major contributors to the fine tuning of gene regulation in a wide array of organisms. microRNAs partner with effector proteins called Argonautes (AGOs), then guide the AGO to target mRNAs to silence gene expression. Recently, heterozygous de novo coding variants in human AGO1 and AGO2 have been shown to disrupt both neural and physical development, thereby directly implicating these variants in a rare neurodevelopmental disorder referred to as Argonaute syndrome. In this study, we are looking to examine the molecular and cellular effects of three specific AGO1 variants: p.(Phe180del), p.(Val254Ile) and p.(His751Leu) on iPSC-derived neurons and glial cells to gain a better understanding of the functions of AGO1, its effect on its small RNA pathways and its influence on cellular pathology in the context Argonaute syndrome. We will perform small RNA-seq, mRNA-seq and Ribo-seq in wild type vs. AGO1 variant cell lines to understand the effects of AGO1 variants on translation as well as the mRNA and sRNA transcriptome. This will broaden our understanding of which small RNAs and mRNA targets are mis-regulated upon AGO1 mutation, and how AGO1 regulates its targets in relevant cell lines. Additionally, we will examine the effects of the AGO1 variants on cellular morphology and neuronal activity using immunofluorescence microscopy and calcium imaging, respectively. This will allow us to gain a more comprehensive view of how these variants are influencing cellular physiology and pathology. The completion of this work will help to reveal critical fundamental information about the mechanisms of Argonaute syndrome, ultimately facilitating the development of novel therapeutic approaches for the treatment of this rare disease.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rughani, Ellanore
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~